New Zealand
Kimer Med is a New Zealand-based startup that aims to make a significant impact in the field of biopharma and biotechnology. Founded in 2020, the company's vision is to put an end to the immense suffering caused by viral diseases. Their mission involves the development, testing, and eventual launch of broad-spectrum antiviral drugs for both humans and animals.
The company recently secured a NZD4.20M investment in a Seed Round, which took place on 31 March 2021. This investment reflects the confidence of the investors in Kimer Med's vision and capabilities. The company's slogan, "We're developing a broad-spectrum antiviral drug. Our goal is to end the suffering of millions of humans and animals," encapsulates their ambitious and noble intentions.
With a clear focus on addressing a critical global health issue, Kimer Med has positioned itself as a promising player in the fight against viral diseases. Their commitment to developing solutions for both human and animal health sets them apart in the biopharma and biotechnology industries.
Given the magnitude of the global viral disease burden, Kimer Med's efforts have the potential to create a positive and lasting impact. Their recent investment and dedication to their cause make them a noteworthy prospect for venture capital consideration.
